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              （1）細彦・’∵Pr・f．」． lshigami，砿D．ノ
Fr・m theエ）吻襯鋸げMicr・bi・1・g］， School ・f rVfedicine， K・be O｝Zゴ薦勿
            （1）irect・r．’P彫8． H・tta，瓦1）りPん．1）．ノ
    Ciinical and experimental studies were performed using Citrobacter freundii organisms which were
isolated from urine specimens of in一 and out－patients who visited our Department between January
1980and Julyユ981． Specimens食om other clinics were examined similarly fbr comparison． The
results are summarized as follews；
    （正）Most of the O㌧伽η薦isolated at our hospital were倉om ul・ille specimens（80％）． At our
department， C． freundii tended to’ be isolated at a higher frequency as the years passed （in－patients，
from 18AO／， （1980） te 19．00／． （1981）； out－patients， from 4．IO／． （Ll 980） to 6．40／， 〈1981））．
    （2） Examination by the disc method showed the C． freundii organisms to be sensitive to AMK
and PL， but to be resistant to 9 other drugs， especial｝y B－lactam antibiotics． Examination by the
MIC method showed the same organisms to be highly sensitive to PPA， FO）vl and GM， as well as
CMX （a B－lactam antibiotic）．
    （3） Phenol coeMcients of Hibitane and Osvan to C， freundii were not particularly， different from
those obtained for the Enterobacteriaceae．
    （4） Experimental urinary tract infection was produced by 12 strains of C． freundii in ’female ddY
mige．．by． iaj．ec．tien ．into．．exp．osed urinary bladd．er． ．
．T4e．Tnopt．ality． ， r4tlo in the ．blqdder infegtion werc calculated at 5 days after inoculation ofbacilli． Strain
No．12 and No．53’ induced a relatively high mortality ratio （1000／6 mortality at an infection dose of 5．0 ×
10s ’bFUIni6Use’ and 7．e× 10s CFU／mouse， respectively）， Rates of recovery of the erganisms from
kidney ’≠獅?urinary bladder of the infected mice were high （In the case of No．12， the recovery rate
was 1000／， when the erganisms of 5．0×104 CFUfmouse were inocu！ated； sirnilarly 1000／． recovery
was attained when the No．58 organisms of 7．0×103 CFUgmouse were inoculated）．
    （5）Histopathologically， the infected kidney showed a severe inflam孤atory reaction associated
with abscess formation and necrosis of medulla， pelvis and papilla． The overall pictures were of
typical acute pyelonephritis．
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freundiiの同定にはAPI－20E（API System S A．， Fra－






benicillin （SB－PC）， cephaloridkie （CER）， cephalexin
（CEX）， cefazolin （CEZ）， gentamicin （GM）， strepto－
mycin （SM）， amikacin （AMK）， dibekacin （DKB），
tetracycline （TC）， minocycline （MINO）， doxycycline
（DO文Y）， chloramphenicol（CP）， polymyxin－B（PL），
colisti．n （CL）， nalidixic acid （NA）， sulfamethizol










pivmecillinam（PM－PC）， BRL－25000， GEX， cefme－
tazole （CMZ）， cefotiam （CTM）， cefoperazone （CP
Z）， cefotaxime （CTX）， ceftizoxime （CZX）， latamo－
xef （LMOX）， cefmenoxime （CMX）， T－1982， SN－
401， aEZ， cefoxitin （CFX）， GM， cinoxacin （CINX），




coccus aureus 209P J（】一1， E∫cherichia coli NI耳J JC－2，
Klebsiella pneumoniae No．13， Pseudomonas aeraginosa
．．
















  a）使用菌株：用いた菌株はC．freundii No．1，
No．7， No．11， No． 12， No． 16， No．21， No．22， No．30，
No．32， No・43， No・45およびNo．53の計12株であ
る．対照菌として」醜6ゐ痂轟θcoli P5101， ProtetiS mor－
ganii Kono， Proteus mirabilis 3003， Klebsiella Pneumoniae
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Fig．1． Annual changes of organisms isolated from u血e specimens of all
    departments． The organisms from other out－patients departments
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Fig． 2． Annual changes of organisms isolated from urine specimens of out－
     patients in Department of Urology．
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Table 1． Number of Citrobacter freundii isolated
     from various specimens and its annual
     changes．
Sample
一 1972圃1980〔1．12｝ P981．     ｛1～7）
105≦ 2 85（h｝71飢｝45（r．）6圃URO
〈105 1 7（in）1圓2（in）Urine
lO5≦ 62 227 49
OTH
く105 6 15 3
URO 0 0 0SputumOTH 5 4 4
URO 0 1 0BbodOTH 1 4 2
URO 0 0 0Bile
OTH 7 12 5
Cerebro・URO 0 0 0spina1
fluidOTH 1 0 1
URO 0 4 0PusOTH 4 16 書2
肺aryngealURO 0 0 0
dischargeOTH 0 1 0
URO 0 0 1Unknown
OTH 0 4 3





















1972 Citrobacter freundiiUroL in （ 
3 ）
Other in （68）
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Fig． 5． Sensitivity distributions of Citrobacter freundii in 1972 by
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Sensitivity distribution of Citrobacter freundii in 1980 by
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Fig．7。 Sensitivity distributions of Citrobacterプ｝eundii in 1981
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Fig． 9． Sensitivity distributions of Serratia marcescens in 1981
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Fig．10 Drug－resistance patterns of Ci’trobacter freundii
    from urine specimens，







 6）石炭酸係数：前述の尿由来C． freundii 53株の
申からNo． 12， No．21およびNo．53を選定し，対
照菌としでS．aureus 209P JG－1， E． coli NIHJ Jc－2，
K． Pneumoniae No．13， Ps． aeruginosa No．12， Pr． mor－
ganii KonQおよび3． marcescens S－9の計9株を用
い，これらに対するヒビテンおよびオスバンの石炭酸
係数を求めた．その成績はTable 3に示される．
対照菌のPs． aeruginosa No．12およびPr． morganii
Konoはヒビテンやオスバンに対して石炭酸係数は小
さく，かなり耐性を示したが，C・ freundiiは腸内細菌







































X＝Not tested in this year
Fig． I l． Drug－resistance patterns of Citrobacter fre－
    undii from out－patients urine specimens．
感染力は，（i）No．53株のごとく7．0×105CFU／mouse
のchallengeで100％mortalityを示すような感染
力の強い株， （ii）No・ll， No．22， No．45のように
107 cFu／mouseのchallengeに対し。％ mortalityを
示すもの，および（iii）その中間の病原性を有する株























































 自然治癒率をTable 6に記した． NQ．30が85．7％
と最も高く，感染力が弱いことを示しており，No．7，
No．16， No．43， No．22， No．32の順であった， No．12
およびNo．53は自然治癒率は低かった（約28％）．
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Table 2． MIC distribgtion of 53 strains of newly isolated O伽bac彪r
     freundii from urine specimens against 24 antimicrobial agents．
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Table 3．．Phenol coef丑cient of H：ibitane and Osvan




C． freundiiNo． 12 15．0
No．21 10．0
No． 53 15． 8
S．aureus 209 P JC－1 12．5





















Hibitane： Chrorhexidine giuconate 5 ％ CW／V）
    Sumitemo Kagaku
Osvan ：Benzalkoniumchloride 1070 〈W／V）





















Mortality and infectivity titrations of ascending kindney
infectlon withα’励αo産6け蜘η薦in mlce．
639
       Cha［lengeC freundii dose
























































































































＊ Mortality was calculated at 5 days after chal｝enge，
＊＊ Bacterial recovery tests were carried out with survived mice
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Mortality and infectivity titrations of ascending kidney
infection with Citrobacter freundii in mice．
      Challenge
（”． freundii dose
























































































































＊ Moftality was calculated at 5 deys after chailenge．
＊＊ Bacteria） recovery tests were carfied eut with survived mice
























 C． fr undiiによる院内感染を予防する目的で，消毒
薬の効果について検討したところ，C・ freundiiは対照
菌中のE．coli NIHJ Jc－2， K． pneumoniae No． 13お
よびS．marcescens S－9と同様の成績で，それらの消
毒薬に比較的殺菌されやすい成績であった．これに対
K．Pneumoniae No．13， Ps． aeruginosa No．12および
Pr． morganii Konoはヒビテンに対し抵抗性を有し






               片岡lCitrobacter ．freundii ．病原性
Table 5． Mortality and infectivity titrations of ascending kidney


















































































































＊ Mortality was calculated at 5
＊＊ Bacterial recovery tests were
  5 days after challenge．
days after challenge．
carried out wi廿1 survivedmice at
Fig． 12． Colonies on DHL platerial recovery by stamping method from
        the kidney and bladder of a mouse infected with No． 12，










chailenge dese dead survived
Number of mice Number of mice Number of mice













































































































5   35，ア
10   66．ア













Tote1 213 41 172 52 30．2 80 46．5 92 53．5
＊ GLK：Number ef rnice which had the gross lesien of kidney
＊＊ NK ：Number ef mice which hed the neeresis of kidney as
   observed microscopicaily．
Fig． 13． The gross lesion of kidney a nd bladder of a mouse at 5 days
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Fig． 14． Low magnification microphotograph of kidney at 5 days
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Fig． 16． The lesion of renal tubles of the same kidney of Fig． 14．
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Table 7． Mortality and infectivity titrations of
     ascending kidney infection with Citro－
     bacter freundii and 7 gram－negative bac－




species strain Kidney Bladder
C， freundii No・ 1
      7
      11
      12
      16
      21
      22
      30
      32
      43
      45
      53
1．48 ＞〈 10i  1．62 × 103   2．5ア × 102
＞Zl x lo7 1．3×lo6 1．3×loe
（5．0 × 107） 6．76 × 104 5．5 × lo4
7．25 × 105 1．32 × 103 3．39 × loS
＞1．0 × 107 1．45 × 10： 1．45 × 105
2．88×107  5．5×104  2．ア5×104
＞3．1 × 10， 4．47 × 105 1．74 × lo5
1．0ア X 107  2．51 × 104    1．0 × 10e
5．25 × loe 1．74 × lo4 s．32 ×le4
 2．1 × 10？ 2．19 × lo5 1．0× 10S
＞ 4．3× 107 5．63 × lo4 4．47 × 104




S， marcescens S一 2
     S－9
1’s，aetuginesa No・12
Pr， mirubilis




 2．0 × lo7
7．1 × los
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